Stocks Health care PRQR
NASDAQ · Health careProQR Therapeutics N.V. (PRQR)
ProQR Therapeutics N.V. reported revenue of €15.9M in fiscal 2025, down 15.9% from a year earlier. It posted a net loss of €42.2M. In fiscal 2025 capital spending exceeded operating cash flow by €53.8M. At December 31, 2025 it held €92.4M in cash against €4.9M of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 12, 2026.
Key facts about ProQR Therapeutics N.V.
- Net worth
- ProQR Therapeutics N.V. has a market value (market cap) of $184.9M at the latest share price, and shareholders' equity of €49.4M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was €15.9M (-15.9% year on year), with a net loss of €42.2M.
- Cash flow
- In fiscal 2025 operations used €52.8M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 12, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What ProQR Therapeutics N.V. does
ProQR Therapeutics N.V. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PRQR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | €15.9M | -€42.2M | -€0.40 | -€53.8M |
| 2024 | €18.9M | -€27.8M | -€0.32 | -€37.8M |
| 2023 | €6.5M | -€28.1M | -€0.35 | €20.2M |
| 2022 | €3.6M | -€64.4M | -€0.90 | -€69.2M |
| 2021 | €1.3M | -€60.7M | -€0.95 | -€26.5M |
| 2020 | n/a | -€46.6M | -€0.93 | -€48M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PRQR ranks in Health care
Latest SEC filings
What ProQR Therapeutics N.V. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 30, 2026
- October 28, 2026
- September 23, 2026
- September 9, 2026
- August 13, 2026
- August 13, 2026
- July 29, 2026Activist stake changed SCHEDULE 13D/A
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- July 15, 2026Passive stake changed SCHEDULE 13G/A
- July 6, 2026Form F-3 filing F-3
Insider trades
What the people running ProQR Therapeutics N.V. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 31, 2026 | de Boer Daniel AntonChief Executive Officer, Director | Bought | 200,000 | $354K |
| July 17, 2026 | Filius BartDirector | Bought | 150,000 | $257.9K |
| July 9, 2026 | de Boer Daniel AntonChief Executive Officer, Director | Bought | 150,000 | $261K |
| July 7, 2026 | de Boer Daniel AntonChief Executive Officer, Director | Bought | 150,000 | $238.5K |
| June 26, 2026 | Filius BartDirector | Bought | 150,000 | $231K |
Who owns PRQR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Van Herk Investments B.V.13D, may seek influence with 8 related filers | 10.9% | July 29, 2026 |
| Aberdeen Group plc13G, passive with 1 related filers | 6.33% | July 29, 2026 |
| Adage Capital Management, L.P.13G, passive with 2 related filers | 6.27% | August 12, 2025 |
| Patrick Johan Hendrik Krol13G, passive with 4 related filers | 5.2% | July 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 70 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Adage Capital Partners GP, L.L.C. | 9,015,897 | +2,762,430 |
| Aberdeen Group plc | 8,932,507 | +5,615,542 |
| Affinity Asset Advisors, LLC | 5,543,936 | +3,089,658 |
| Privium Fund Management B.V. | 5,520,024 | +52,875 |
| Ikarian Capital, LLC | 3,425,930 | +1,933,701 |
| Woodline Partners LP | 3,277,143 | new |
| Heights Capital Management, Inc | 2,762,430 | new |
| Morgan Stanley | 1,767,215 | +467,440 |
| Sphera Funds Management Ltd. | 1,757,458 | new |
| Kynam Capital Management, LP | 1,566,317 | 0 |
| DAFNA Capital Management LLC | 1,530,361 | -37,200 |
| Squadron Capital Management LLC | 1,511,496 | new |
| 683 Capital Management, LLC | 1,393,067 | new |
| Citadel Advisors LLC | 1,184,314 | +480,991 |
| Platinum Investment Management Ltd | 1,159,428 | -76,086 |
| Two Sigma Investments, LP | 1,138,715 | +219,858 |
| Eversept Partners, LP | 1,022,265 | new |
| Boothbay Fund Management, LLC | 948,736 | +593,453 |
| Diadema Partners LP | 926,016 | +745,933 |
| UBS Group AG | 639,243 | +333,979 |
Insiders
2 insiders reported holding 800,000 shares in total, about $1M at the last price.
| Holder | Shares |
|---|---|
| de Boer Daniel AntonChief Executive Officer, Director | 500,000 |
| Filius BartDirector | 300,000 |
Questions about PRQR
What does ProQR Therapeutics N.V. do?
ProQR Therapeutics N.V. is a company in the Health care sector, listed on NASDAQ as PRQR. Its shares trade on NASDAQ under the ticker PRQR.
What is ProQR Therapeutics N.V.'s net worth?
ProQR Therapeutics N.V. has a market value (market cap) of $184.9M at the latest share price, and shareholders' equity of €49.4M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is ProQR Therapeutics N.V. profitable?
No. In fiscal 2025 it reported a net loss of €42.2M on revenue of €15.9M.
How much revenue does ProQR Therapeutics N.V. make?
In fiscal 2025 ProQR Therapeutics N.V. reported revenue of €15.9M. That is 15.9% less than a year earlier.
When did ProQR Therapeutics N.V. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 12, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update (amended) from October 30, 2026.
Similar companies
Compare PRQR with
Follow PRQR
Get an email when ProQR Therapeutics N.V. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values ProQR Therapeutics N.V. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.